Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

WuXi AppTec Pays $135 Million to Acquire Oxgene, a Gene Therapy CDMO

WuXi AppTec, a China-global CRO/CMO, paid $135 million to acquire Oxgene, a UK CDMO that develops scaleable gene technologies to develop cell and gene therapies. Previously, WuXi 's gene therapy unit licensed Oxgene's novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions. WuXi found the technology a big improvement over the competition and wanted to invest in Oxgene, but ended up acquiring the entire company. Oxgene will become part of WuXi Advanced Therapies, WuXi 's year-old cell and gene therapy Contract Testing, Development and Manufacturing Organization unit. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.